1.
Blood
; 2024 Jun 25.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38917352
RESUMEN
Tyrosine kinase inhibitors have improved outcomes in Philadelphia-positive ALL, but their efficacy in CNS disease remains uncertain. Ponatinib was studied for CNS distribution in 22 samples from 16 patients. CSF concentrations fell below the 40nM threshold, suggesting suboptimal CNS exposure.